Latest Breaking News On - Matthijs moerland - Page 1 : comparemela.com

(2) OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM s drug Ampligen as an intranasal therapy, a critical step in the company s ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases. Earlier this year, the company announcedthat it had entered into a sponsorship agreement with the Centre for Human Drug Research (CHDR) for the proposed AMP-COV-100 (CHDR2049) trial. Last week, approval was received from the Dutch local Ethics Committee, clearing the road for execution of the trial.

United statesMatthijs moerlandThomask equelsCentre for human drug researchImmunotech incCrescendo communicationsEthics committeeHuman drug researchAntiviral researchUtah state universityPrivate securities litigation reform actஒன்றுபட்டது மாநிலங்களில்மையம் க்கு மனிதன் மருந்து ஆராய்ச்சிபிறை தகவல்தொடர்புகள்நெறிமுறைகள் குழுமனிதன் மருந்து ஆராய்ச்சி